Clinical trial · no report yet · Phase 2
c-TRAK-TN
A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients
- NCT03145961 ↗
- Unknown
- Institute of Cancer Research, United Kingdom
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 6 | |
| X threads | 5 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- c-TRAK TN: A Randomised Trial Utilising ctDNA Mutation Tracking to Detect Minimal Residual Disease and Trigger Intervention in Patients With Moderate and High Risk Early Stage Triple Negative Breast Cancer
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Pembrolizumab
- Arms
- Observation · No intervention
- Pembrolizumab Treatment · Experimental
- Enrollment
- 208
- Primary outcomes
- Positive ctDNA detection by 12 months
- Positive ctDNA detection by 24 months
- Absence of detectable ctDNA or disease recurrence 6 months (24 weeks) after commencing pembrolizumab
- Sponsor
- Institute of Cancer Research, United Kingdom with National Institute for Health Research Biomedical Research Centre at the Royal Marsden / Institute of Cancer Research UK, Merck Sharp & Dohme LLC
- Start
- Dec 21, 2017
- Primary completion
- Sep 30, 2021
- Results posted
- No
- Registry record
- NCT03145961 · updated Feb 24, 2022
Publications
linked from the registry- Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek P, Hall P, Harper-Wynne C, Hickish T, Kernaghan S, Macpherson IR, Okines AFC, Palmieri C, Perry S, Randle K, Snowdon C, Stobart H, Wardley AM, Wheatley D, Waters S, Winter MC, Hubank M, Allen SD, Bliss JM; c-TRAK TN investigators. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol. 2023 Feb;34(2):200-211. doi: 10.1016/j.annonc.2022.11.005. Epub 2022 Nov 22. PubMed 36423745